Three Phase III Studies of Imbruvica Presented at ASCO Annual Meeting

EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC

The European Medicines Agency approved Calquence (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant.

May 09, 2025

Vol.51 No.18

In Brief

Brian Druker, developer of Gleevec, crosses Boston Marathon finish line alongside daughter Julia

Brian Druker ran the marathon with his daughter, Julia, to celebrate her May 2025 college graduation and law school applications (The Cancer Letter, April 4, 2025).

May 02, 2025

Vol.51 No.17

Drugs & Targets

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone, a chemotherapy regimen, in adult patients with newly diagnosed stage 2b with risk factors/3/4 Hodgkin lymphoma.

May 02, 2025

Vol.51 No.17

Clinical Roundup

Genetic mutations link could lead to new therapies for AML

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Memorial Sloan Kettering Cancer Center in New York have found a link between two genetic mutations in a subtype of acute myeloid leukemia, which could lead to new ways to treat the disease.

April 25, 2025

Vol.51 No.16

Clinical Roundup

MSK and City of Hope researchers develop test using machine learning to help predict immunotherapy response in lymphoma

Researchers with Memorial Sloan Kettering and City of Hope have created a tool that uses machine learning to assess a non-Hodgkin lymphoma patient’s likely response to chimeric antigen receptor T-cell therapy before starting the treatment, according to study results published on April 1 in Nature Medicine.

April 11, 2025

Vol.51 No.14

Clinical Roundup

NK cells complexed with bispecific antibody yield high response rates in lymphoma

A novel cell therapy approach using cord blood-derived natural killer cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from the University of Texas MD Anderson Cancer Center.

April 11, 2025

Vol.51 No.14

Three Phase III Studies of Imbruvica Presented at ASCO Annual Meeting

YOU MAY BE INTERESTED IN

EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC

Brian Druker, developer of Gleevec, crosses Boston Marathon finish line alongside daughter Julia

CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma

Genetic mutations link could lead to new therapies for AML

MSK and City of Hope researchers develop test using machine learning to help predict immunotherapy response in lymphoma

NK cells complexed with bispecific antibody yield high response rates in lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login